Current status of antiretroviral therapy

Bibliography

• PALELLA FJ Jr, DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. (1998) 338:853-860.
   PubMed Web of Science ®Google Scholar
• TORRES RA, BARR M: Impact of combination therapy for HIV infection on inpatient census. N. Engl. J. Med. (1997) 336:1531-1532.
   PubMed Web of Science ®Google Scholar
• HASELTINE WA: Molecular biology of the human immunodeficiency virus type 1. FASEB J. (1991) 5(10):2349-2360.
   PubMed Web of Science ®Google Scholar
• MITSUYA H, BRODER S: Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus III/ lymphadenopathy-associated virus (HTLV III/LAV) by 2′, 3′-dideoxy- nucleosides. Proc. Natl. Acad. Sci. USA (1986) 83:1911-1915.
   Google Scholar
• GAO WY, AGBARIA R, DRISCOLL JS, MITSUYA H: Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. (1994) 269(17):12633-12638.
   PubMed Web of Science ®Google Scholar
• GROB PM, WU JC, COHEN KA et al.: Nonnucleoside inhibitors of HIV-1 reverse-transcriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses (1992) 8:145-152.
   PubMed Web of Science ®Google Scholar
• MERLUZZI VJ, HARGRAVE KD, LABADIA M et al.: Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science (1990) 250:1411-1413.
   PubMed Web of Science ®Google Scholar
• WITVROUW M, PANNECOUQUE C, SWITZER WM, FOLKS TM, DE CLERCQ E, HENEINE W: Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral Therapy (2004) 9(1):57-65.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE LL, GREENBLATT DJ, GRANDA BW et al.: Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J. Clin. Pharmacol. (2001) 41(1):85-91.
   PubMed Web of Science ®Google Scholar
• POLLARD RB, ROBINSON P, DRANSFIELD K: Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Ther. (1998) 20:1071-1092.
   PubMed Web of Science ®Google Scholar
• ANANWORANICH J, MOOR Z, SIANGPHOE U et al.: Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS (2005) 19(2):185-192.
   PubMed Web of Science ®Google Scholar
• SULKOWSKI MS, THOMAS DL, MEHTA SH, CHAISSON RE, MOORE RD: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 35(1):182-189.
   PubMed Web of Science ®Google Scholar
• NUNEZ M, LANA R, MENDOZA JL, MARTIN-CARBONERO L, SORIANO V: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2001) 27(5):426-431.
   Google Scholar
• DE SANTIS M, CARDUCCI B, DE SANTIS L, CAVALIERE AF, STRAFACE G: Periconceptional exposure to efavirenz and neural tube defects. Arch. Intern. Med. (2002) 162(3):355.
   PubMedGoogle Scholar
• FUNDARO C, GENOVESE O, RENDELI C, TAMBURRINI E, SALVAGGIO E: Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS (2002) 16(2):299-300.
   PubMed Web of Science ®Google Scholar
• VAN LETH F, PHANUPHAK P, RUXRUNGTHAM K et al.: 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet (2004) 363(9417):1253-1263.
   PubMed Web of Science ®Google Scholar
• NAVIA MA, FITZGERALD PM, MCKEEVER BM et al.: Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (1989) 159:87-94.
   Google Scholar
• PILLAY D, BRYANT M, GETMAN D et al.: HIV-1 protease inhibitors: their development, mechanism of action and clinical potential. Rev. Med. Virol. (1995) 5:23-33.
   Google Scholar
• KUMAR GN, RODRIGUES AD, BUKO AM et al.: Cytochrome P450- mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. (1996) 277:423-431.
   PubMed Web of Science ®Google Scholar
• KEMPF DJ, MARSH KC, KUMAR G et al.: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. (1997) 41:654-660.
   PubMed Web of Science ®Google Scholar
• GERBER JG: Using pharmacokinetics to optimize antiretroviral drug–drug interactions in the treatment of human immunodeficiency virus infection. Clin. Infect. Dis. (2000) 30(Suppl. 2):S123-S129.
   PubMed Web of Science ®Google Scholar
• ECKERT DM, KIM PS: Mechanism of viral membrane fusion and its inhibition. Ann. Rev. Biochem. (2001) 70:777-810.
   PubMed Web of Science ®Google Scholar
• COOLEY LA, LEWIN SR: HIV-1 cell entry and advances in viral entry inhibitor therapy. J. Clin. Virol. (2003) 26:121-132.
   Google Scholar
• LALEZARI JP, HENRY K, O’HEARN M et al.: TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. (2003) 348(22):2175-2185.
   PubMed Web of Science ®Google Scholar
• LAZZARIN A, CLOTET B, COOPER D et al.: TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. (2003) 348(22):2186-2195.
   PubMed Web of Science ®Google Scholar
• TROTTIER B, WALMSLEY S, REYNES J et al.: Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J. Acquir. Immune Defic. Syndr. (2005) 40(4):413-421.
   PubMed Web of Science ®Google Scholar
• GROSSMAN HA, HICKS C, NADLER J et al.: Efficacy and tolerability of TMC125 in HIV patients with NNRTI and PI resistance at 24 weeks: TMC125-c223. In: Program and Abstracts of the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, December 16-19 (2005) Washington, DC, USA. Abstract H-416c.
   Google Scholar
• KATLAMA C, CARVALHO MI, COOPER D et al.: TMC 114/r out performs investigator selected PI(s) in three class-experienced patients: week 24 primary analysis of POWER 1 (TMC 114-C213). In: Program and Abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, July 24-27 (2005), Rio de Janeiro, Brazil. Abstract WeOaLB0102.
   Google Scholar
• WILKIN T, HAUBRICH R, STEINHART CR et al.: TMC114/r superior to standard of care in 3-class-experienced patients: 24-wks primary analysis of the Power 2 Study (C202). In: Program and Abstracts of the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, December 16-19 (2005), Washington, DC, USA. Abstract H-413.
   Google Scholar
• CRAIGIE R: HIV integrase, a brief overview from chemistry to therapeutics. J. Biol. Chem. (2001) 276(26):23213-23216.
   Google Scholar
• GRINSZTEJN B, NGUYEN BY, KATLAMA C et al.: Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, (2006) Denver, Colorado, USA. Abstract 159LB.
   Google Scholar
• MOORE JP, DOMS RW: The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. USA (2003) 100:10598-10602.
   Google Scholar
• LUCAS AD, GAUDIERI S, RAUCH A et al.: Cellular tropism of HIV-1 mediated and constrained by coreceptor dependencies. J. Viral Entry (2005) 1:17-27.
   Google Scholar
• PHILPOTT SM: HIV-1 coreceptor usage, transmission, and disease progression. Curr. HIV Res. (2003) 1:217-227.
   Google Scholar
• MOYLE GJ, WILDFIRE A, MANDALIA S et al.: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. (2005) 191(6):866-872.
   PubMed Web of Science ®Google Scholar
• STEEL HM: Special presentation on aplaviroc-related hepatotoxicity. In: Program and Abstracts of the European AIDS Clinical Society 10th European AIDS Conference, November 17-20 (2005), Dublin, Ireland.
   Google Scholar
• MCHALE M, ABEL S, RUSSELL D et al.: Overview of Phase I and 2a safety and efficacy data of maraviroc (UK-427,857). In: Program and Abstracts of the 3rd International AIDS Society Conference on the HIV Pathogenesis and Treatment, July 24-27 (2005), Rio de Janeiro, Brazil. Abstract TuOa0204.
   Google Scholar
• LI F, GOILA-GAUR R, SALZWEDEL K et al.: PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. (2003) 100(23):13555-13560.
   Google Scholar
• BEATTY G, LALEZARI J, ERON J et al.: Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. In: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19 (2005), Washington, DC, USA. Abstract H-416d.
   Google Scholar
• YENI PG, HAMMER SM, HIRSCH SM et al.: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 292:251-265.
   PubMed Web of Science ®Google Scholar
• STASZEWSKI S, KEISER P, MONTANER JS et al.: Abacavir-lamivudine-zidovudine versus indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults: a randomized equivalence trial. JAMA (2001) 285(9):1155-1163.
   PubMed Web of Science ®Google Scholar
• VIBHAGOOL A, CAHN P, SCHECHTER M et al.: Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-weekopen-label, equivalence trial (CNA3014). Curr. Med. Res. Opin. (2004) 20(7):1103-1114.
   PubMed Web of Science ®Google Scholar
• VAN LEEUWEN R, KATLAMA C, MURPHY RL et al.: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 17(7):987-999.
   PubMed Web of Science ®Google Scholar
• BARTLETT JA, JOHNSON J, HERRERA G et al.: Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS4001(CLASS) preliminary 48 week results. In: XIV International AIDS Conference; July 7-12 (2002), Barcelona, Spain. Abstract TuOrB1189.
   Google Scholar
• GERSTOFT J, KIRK O, OBEL N et al.: Low efficacy and high frequencyof adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS (2003) 17(14):2045-2052.
   PubMed Web of Science ®Google Scholar
• PECORA FULCO P, KIRIAN MA: Effect of tenofovir on didanosine absorption in patients with HIV. Ann. Pharmacother. (2003) 37:1325-1328.
   PubMed Web of Science ®Google Scholar
• JEMSEK J, HUTCHERSON P, HARPER E: Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In: 11th Conference on Retroviruses and Opportunistic Infections; February (2004), San Francisco, CA, USA.
   Google Scholar
• LEON A, MARTINEZ E, MALLOLAS J et al.: Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS (2005) 19:213-215.
   PubMed Web of Science ®Google Scholar
• PODZAMCZER D, FERRER E, GATELL JM et al.: Early virological failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. Antiviral Therapy (2004) 9:S172.
   Google Scholar
• BARRIOS A, RENDONA, NEGREDO E et al.: Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 19(6):569-575.
   PubMed Web of Science ®Google Scholar
• LACOMBE K, PACANOWSKI J, MEYNARD JL et al.: Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. AIDS (2005) 19(10):1107-1108.
   PubMed Web of Science ®Google Scholar
• NEGREDO E, BONJOCH A, PAREDES R et al.: Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clin. Infect. Dis. (2005) 41(6):901-905.
   PubMed Web of Science ®Google Scholar
• COTE H, MAGIL A, HARRIGAN PR et al.: Kidney mitochondrial DNA levels in HIV patients with renal dysfunction on tenofovir-containing therapy are markedly reduced with concurrent didanosine therapy. In: Program and Abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, July 24-27, Rio de Janiero, Brazil (2005). Abstract TuPe2.3C19.
   Google Scholar
• LOUIE S, BALLARD C, BI L, BERINGER P: Factors increasing the risk of renal dysfunction with tenofovir difumarate (TDF). In: Program and Abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, July 24-27, Rio de Janiero, Brazil (2005). Abstract TuPe3.5B01.
   Google Scholar